News | June 02, 2009

Nucletron Merges with Isodose Control BV

June 2, 2009 – Nucletron BV, a cancer radiation solutions company, has created of an exclusive partnership and plans to merge with sector peer Isodose Control BV for an undisclosed sum.

The two companies, headquartered in Veenendaal and Ede, the Netherlands, are complementary and the combination will strengthen Nucletron’s position as a global leader in the market for high-precision radiation therapy equipment and software for brachytherapy.

The merger plans were announced by the two companies’ CEOs June 1 in Toronto, Canada, at the American Brachytherapy Society’s annual conference.

“By combining strengths we will become the undisputed global market leader in brachytherapy, which offers quality, safe and effective treatment options for the most frequently occurring kinds of cancer,’’ said Jos Lamers, CEO of Nucletron.

Nucletron is the world’s number one medical equipment provider in the brachytherapy market, with a strong focus on customer support; Isodose Control has grown in six years to become number three and has an impressive product innovation track record.

“Isodose Control has developed a range of innovative brachytherapy products and has a promising range in development. Together with Nucletron, we look forward to speeding up the market introductions of these innovations to healthcare institutions and their patients worldwide,” said Eric van’t Hooft, CEO of Isodose Control BV.

Nucletron reported EBITDA of € 17 million on net sales of € 112.4 million in 2008.

For more information: www.nucletron.com

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
News | Brachytherapy Systems, Women's Healthcare | October 25, 2018
iCAD Inc. announced new clinical research demonstrating positive outcomes supporting the use of the Xoft Axxent...
Xoft Electronic Brachytherapy System Effective Long-Term for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | October 02, 2018
Breast cancer recurrence rates for patients treated with the Xoft Axxent Electronic Brachytherapy (eBx) System that...
Varian Showcases Advanced Cancer Care Solutions at AAPM 2018
News | Radiation Therapy | July 27, 2018
Varian announced it will be showcasing its advanced cancer care solutions, including a new version of the Eclipse...
Florida Hospital First in State to Adopt NeuroLogica's BodyTom Elite CT
News | Computed Tomography (CT) | June 14, 2018
June 14, 2018 — NeuroLogica, a subsidiary of Samsung Electronics Co.
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Combination Radiotherapy Beneficial in Treating Prostate Cancer
News | Prostate Cancer | March 27, 2018
March 27, 2018 — While there are many treatment options for men with...